Trending News

Trump Administration Issues AI Action Plan and AI Executive Orders

Winning the Race: America’s AI Action Plan

Innovation Over Regulation – Trump Unveils America’s AI Action Plan

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
Posted On Tuesday, July 29, 2025
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Posted On Tuesday, July 29, 2025
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Posted On Tuesday, July 29, 2025
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
Posted On Tuesday, July 29, 2025
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
Posted On Tuesday, July 29, 2025
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Posted On Tuesday, July 29, 2025
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
Posted On Tuesday, July 29, 2025
Concept Life Sciences & Fios Genomics Partner to Enhance Complex Data Analysis in Drug Discovery
Posted On Tuesday, July 29, 2025
LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
Posted On Tuesday, July 29, 2025
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Posted On Monday, July 28, 2025
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status
Posted On Monday, July 28, 2025
Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results
Posted On Monday, July 28, 2025
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
Posted On Monday, July 28, 2025
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Posted On Monday, July 28, 2025
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025
Posted On Monday, July 28, 2025
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
Posted On Monday, July 28, 2025
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Posted On Monday, July 28, 2025
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Posted On Monday, July 28, 2025
Full Alliance Group Reports Second Quarter Preliminary results, Unveils Expansion into High-Growth Men's Wellness Personal Care and Health Virility segment, Association Digital Benefits, and Expands its Contract Manufacturing Markets
Posted On Monday, July 28, 2025
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Posted On Monday, July 28, 2025
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
Posted On Monday, July 28, 2025
Aclaris Therapeutics Announces Leadership Transition
Posted On Monday, July 28, 2025
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
Posted On Monday, July 28, 2025
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Posted On Monday, July 28, 2025
IMUNON Announces Stock Dividend Boosting Shareholder Value
Posted On Monday, July 28, 2025

Print